SIRT1
NAD-dependent protein deacetylase sirtuin-1
As of the edition of 20 October 2026, SIRT1 (NAD-dependent protein deacetylase sirtuin-1, UniProt Q96EB6) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96EB6
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 9
- Disease areas
- Hormones; Inherited and neonatal; Mental health; Nervous system; Nutrition and metabolism; Digestive system; Lungs and airways; Skin and connective tissue
- Registered trials of its drugs
- 11
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| SRT-2104 | Went quiet | Phase 1 | none listed |
| SEN0014196 | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| GSK | Route A |
| Siena Biotech | Route A |
The other 0 companies at SIRT1
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at SIRT1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.